Virus-induced autoimmunity: epitope spreading to myelin autoepitopes in Theiler's virus infection of the central nervous system - PubMed (original) (raw)
Review
Virus-induced autoimmunity: epitope spreading to myelin autoepitopes in Theiler's virus infection of the central nervous system
S D Miller et al. Adv Virus Res. 2001.
Abstract
Epidemiological studies indicate that host immunogenetics and history of infection, particularly by viruses, may be a necessary cofactor for the induction of a variety of autoimmune diseases. To date, however, there is no clear-cut evidence, either in experimental animal models or in human autoimmune disease, that supports either molecular mimicry (Wucherpfennig and Strominger, 1995; Fujinami and Oldstone, 1985) or a role for superantigens (Scherer et al., 1993) in the initiation of T cell-mediated autoimmunity. In contrast, the current data provide compelling evidence in support of a major role for epitope spreading in the induction of myelin-specific autoimmunity in mice persistently infected with TMEV. It is significant that two picornaviruses closely related to TMEV, coxsackievirus (Rose and Hill, 1996) and encephalomyocarditis virus (EMCV) (Kyu et al., 1992), have been similarly shown to persist (either the viral RNA or the infectious virus) in their target organs and have been associated with the development of chronic autoimmune diseases, including myocarditis and diabetes. Thus, inflammatory responses induced by viruses that trigger proinflammatory Th1 responses, and have the ability to persist in genetically susceptible hosts, may lead to chronic organ-specific autoimmune disease via epitope spreading. Epitope spreading has important implications for the design of antigen-specific therapies for the potential treatment of MS and other autoimmune diseases. This process indicates that autoimmune diseases are evolving entities and that the specificity of the effector autoantigen-specific T cells varies during the chronic disease process. Our experiments employing tolerance in R-EAE clearly indicate that antigen-specific treatment of ongoing disease is possible for preventing disease relapses, provided the proper relapse-associated epitope is targeted (Vanderlugt et al., 1999). However, the ability to identify relapse-associated epitopes in humans will be a difficult task because immunodominance will vary in every individual. The use of costimulatory antagonists that can induce anergy without requiring prior knowledge of the exact epitopes (Miller et al., 1995b), or the use of therapies that induce bystander suppression (Nicholson et al., 1997; Brocke et al., 1996), may thus be more practical current alternative therapies for the treatment of human autoimmune disease.
Similar articles
- Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice.
Katz-Levy Y, Neville KL, Girvin AM, Vanderlugt CL, Pope JG, Tan LJ, Miller SD. Katz-Levy Y, et al. J Clin Invest. 1999 Sep;104(5):599-610. doi: 10.1172/JCI7292. J Clin Invest. 1999. PMID: 10487774 Free PMC article. - CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.
Neville KL, Dal Canto MC, Bluestone JA, Miller SD. Neville KL, et al. J Virol. 2000 Sep;74(18):8349-57. doi: 10.1128/jvi.74.18.8349-8357.2000. J Virol. 2000. PMID: 10954534 Free PMC article. - Functional role of epitope spreading in the chronic pathogenesis of autoimmune and virus-induced demyelinating diseases.
Miller SD, Eagar TN. Miller SD, et al. Adv Exp Med Biol. 2001;490:99-107. doi: 10.1007/978-1-4615-1243-1_10. Adv Exp Med Biol. 2001. PMID: 11505979 Review. - The functional significance of epitope spreading and its regulation by co-stimulatory molecules.
Vanderlugt CL, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, Bluestone JA, Miller SD. Vanderlugt CL, et al. Immunol Rev. 1998 Aug;164:63-72. doi: 10.1111/j.1600-065x.1998.tb01208.x. Immunol Rev. 1998. PMID: 9795764 Review.
Cited by
- Immunological and virological triggers of type 1 diabetes: insights and implications.
Lemos JRN, Hirani K, von Herrath M. Lemos JRN, et al. Front Immunol. 2024 Jan 4;14:1326711. doi: 10.3389/fimmu.2023.1326711. eCollection 2023. Front Immunol. 2024. PMID: 38239343 Free PMC article. Review. - The Role of Viral Infections in the Onset of Autoimmune Diseases.
Sundaresan B, Shirafkan F, Ripperger K, Rattay K. Sundaresan B, et al. Viruses. 2023 Mar 18;15(3):782. doi: 10.3390/v15030782. Viruses. 2023. PMID: 36992490 Free PMC article. Review. - Autoimmune complications of COVID-19.
Yazdanpanah N, Rezaei N. Yazdanpanah N, et al. J Med Virol. 2022 Jan;94(1):54-62. doi: 10.1002/jmv.27292. Epub 2021 Aug 31. J Med Virol. 2022. PMID: 34427929 Free PMC article. Review. - Identifying the culprits in neurological autoimmune diseases.
Acosta-Ampudia Y, Monsalve DM, Ramírez-Santana C. Acosta-Ampudia Y, et al. J Transl Autoimmun. 2019 Sep 6;2:100015. doi: 10.1016/j.jtauto.2019.100015. eCollection 2019 Dec. J Transl Autoimmun. 2019. PMID: 32743503 Free PMC article. Review. - Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms.
Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Smatti MK, et al. Viruses. 2019 Aug 19;11(8):762. doi: 10.3390/v11080762. Viruses. 2019. PMID: 31430946 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources